Seprafilm Ordering Options

Seprafilm is available in several configurations, varying in membrane size and quantity, as follows. Surgeons should use discretion to determine how much Seprafilm is required in each procedure to ensure adequate coverage to protect traumatized tissues and organs against adhesions.

To order Seprafilm or for more information, call 1-800-261-1570

Product Code / Catalog Number	Configuration	Pouch Contents	Individual Sheet Size	Packaging
Product Code/Catalog Number 4301-02	Configuration* Seprafilm Adhesion Barrier	Pouch Contents 1 full sheet	Individual Sheet Size 1 (5" x 6") sheet/pouch	Packaging 10 pouches/box
Product Code/Catalog Number 6380-01	Configuration* Seprafilm 4-Section	Pouch Contents 4 quarter sheets	Individual Sheet Size 4 (3" x 2.5") sheets/pouch	Packaging 10 pouches/box
Product Code/Catalog Number 6642-01	Configuration* Seprafilm Small Incision	Pouch Contents 2 half sheets	Individual Sheet Size 2 (3" x 5") sheets/pouch	Packaging 10 pouches/box
Product Code/Catalog Number 5086-02	Configuration* Seprafilm Procedure Pack	Pouch Contents 6 half sheets	Individual Sheet Size 6 (3" x 5") sheets/pouch	Packaging 5 pouches/box

Indication

Seprafilm Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder.

Important Safety Information

Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak-related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in pregnancy; in the presence of frank infection; or malignancies in the abdominopelvic cavity. The product is not recommended for use in pregnant women and conception should be avoided during the first complete menstrual cycle after Seprafilm Adhesion Barrier usage.

Long term clinical outcomes such as chronic pain and infertility have not been determined in clinical studies. Foreign body reactions may occur with Seprafilm Adhesion Barrier, as with any implanted material. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

IMPORTANT SAFETY INFORMATION

Seprafilm Ordering Options

Related Content

Seprafilm in action

Indication

Important Safety Information